“So we're gonna look at a comparator with a slightly lower dose of self-control, and then that'll read out, I would say, by Q3 or so.”

In context

“t we've observed is that you see immediate efficacy and then you see that efficacy held on for quite some time. So that's a benefit. And these patients are then able to stay for a short time in the clinic and then leave. The other notable differences from any other medications in this space are the very high levels of efficacy that were observed, and that almost led to a remission-like state in the majority of patients. Now we have two more readouts before the phase three begins. And in those readouts, what we're doing is reducing the dose of the control arm. And recall data that we've seen thus far were not against placebo; they were, in fact, against an active control of the drug itself, which that data looked pretty good. But when you looked at the main dose, it looked very impressive. So we're gonna look at a comparator with a slightly lower dose of self-control, and then that'll read out, I would say, by Q3 or so. And then we'll have a phase three plan going forward that we'll discuss with regulators. But this has the potential to be highly differentiated. Elizabeth Shea: Operator, next question, please. Operator: Yes. The next question is from Christopher Schott with JPMorgan. Your line is open. Christopher Schott: Great. Thanks. Much. Just a couple parter on the immunology franchise. I guess just first on SKYRIZI in IBD. It sounds like you haven't really seen any change in new start share here with the Tremfya entry. As my question, is that the case in both Crohn's and UC, or is that just more a holistic kind of IBD comment? And my kind of bigger picture question is, I've been reading more investors feeling that the Street now better understands the potential for SKYRIZI and RINVOQ over time. As”